Comparative Study
Journal Article
Add like
Add dislike
Add to saved papers

Comparison of T2-weighted MRI with and without fat suppression for differentiating renal angiomyolipomas without visible fat from other renal tumors.

OBJECTIVE: The purpose of this study was to retrospectively compare the usefulness of T2-weighted imaging with and without fat suppression for differentiating angiomyolipomas (AMLs) without visible fat from other renal tumors.

MATERIALS AND METHODS: MRI was performed in 111 patients (66 men and 46 women; age range, 17-78 years) who had pathologically diagnosed (14 AMLs, 86 renal cell carcinomas [RCCs], and three other tumors) and clinically diagnosed (eight AMLs) renal masses without visible fat or a cystic portion on unenhanced CT. The signal intensity (SI), tumor-to-kidney SI ratio, tumor-to-spleen SI ratio on T2-weighted imaging and fat-suppressed T2-weighted imaging, and tumor-fat subtraction index were measured for each tumor. Receiver operating characteristic (ROC) analysis was used to evaluate diagnostic accuracy of SI ratios.

RESULTS: The highest area under the ROC curve was 0.886 for tumor-to-kidney SI ratio on fat-suppressed T2-weighted imaging. With a tumor-to-kidney SI ratio of 0.9 on fat-suppressed T2-weighted imaging, the sensitivity, specificity, positive predictive value, and negative predictive value were 90.9%, 71.1%, 43.5%, and 97%, respectively. The highest tumor-to-kidney SI ratio of AMLs without visible fat was 1.09. Ninety-eight percent of renal tumors with a tumor-to-kidney SI ratio greater than 1.09 were RCCs (51/52), especially clear cell RCCs (82.7%, 43/52).

CONCLUSION: Fat-suppressed T2-weighted imaging is more useful than T2-weighted imaging for differentiating AMLs without visible fat from non-AMLs. The high SI of solid renal masses on fat-suppressed T2-weighted imaging can be indicative of non-AMLs, especially RCCs.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app